Breaking News

GENinCode, EVERSANA Enter Major U.S. Commercialization Pact

EVERSANA will support launch and commercialization in the U.S. market for GENinCode’s portfolio of polygenic cardiovascular disease products.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GENinCode UK Ltd., a company focused on predictive genetics for the prevention of cardiovascular disease, has selected EVERSANA Life Sciences LLC as its launch and commercialization partner to access the U.S. market for GENinCode’s portfolio of polygenic cardiovascular disease (CVD) products focused on genetic risk.   EVERSANA is a provider of global commercial services to the life sciences industry. In the U.S., GENinCode will use EVERSANA’s COMPLETE Commercialization model of services that i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters